Black Diamond Therapeutics Announces Expected 2024 Milestones; Co. Exploring The Potential Development Of BDTX-1535 In First-line Patients Who Are Post-Osimertinib Adjuvant Treatment.
Black Diamond Therapeutics Announces Expected 2024 Milestones; Co. Exploring The Potential Development Of BDTX-1535 In First-line Patients Who Are Post-Osimertinib Adjuvant Treatment.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.